Skip to content

Hematopoietic Stem Cell Therapy in Chronic Wounds Using a Pressure Sore Model

Effect of Hematopoietic Stem Cells in Chronic Wounds Using a Pressure Sore Model: A Pilot Study on Feasibility, Safety and Potential Effects

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00535548
Enrollment
Unknown
Registered
2007-09-26
Start date
2007-01-31
Completion date
2007-12-31
Last updated
2007-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Wounds, Pressure Sores, Hematopoietic Stem Cells, Wound Healing

Keywords

Chronic wounds, Pressure sores, Hematopoietic stem cells, Wound healing

Brief summary

Aim of the study: Evaluation of feasibility, safety and potential effects of stem cells on chronic wounds using a pressure sore model. Clinical relevance: * Accelerated healing of uncomplicated wounds * Enhanced healing of complicated (chronic, non-healing) wounds Study design: * Prospective controlled phase I/II study * Cohort of 5 patients in pilot study, then reevaluation Patients: \- Para- and tetraplegic patients with sacral pressure sores grade III-IVA according to the classification of Daniel and Seiler Methods: 1\. First surgical intervention: * Radical debridement of pressure sore * Bone marrow harvest from the iliac crest * Isolation of hematopoietic stem cells, aiming to gain \> 1 mio. CD 34+ cells per patient under GMP conditions 3\. Stem cell therapy (after 2 days) * Injection of stem cells in suspension (50'000 CD 34+ cells in 100 microliter saline per cm2 of wound surface) on one half of the total wound surface and cell-free saline on the other half as a control 4\. Second surgical intervention (after 3-4 weeks): * Complete excision of the wound * Closure of the defect by fasciocutaneous flap 5\. Evaluation of wound healing: * Clinical * 3D laser imaging * Histology * Growth factor assay

Interventions

Injection of a hematopoietic stem cell suspension (50'000 CD 34+ cells per microliter) into the wound (1 microliter per cm2 of wound surface)

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Para- or tetraplegic * Sacral pressure sores * Grade III-IV according to classification of Daniel and Seiler

Exclusion criteria

* Diabetes mellitus * Peripheral vascular disease * Coronary artery disease * Smoking * Steroids and other immunosuppressive drugs * Systemic autoimmune or rheumatoid diseases * HIV * Hepatitis B/C

Design outcomes

Primary

MeasureTime frame
feasibility, safety, efficacy1 yr

Countries

Switzerland

Contacts

Primary ContactOliver Scheufler, MD, PhD
oscheufler@gmx.net+41-61-265 2525

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026